Emerging markets not all rosy, experts warn Chinese biotechs

By Wang Fangqing

As geopolitical tension intensifies between China and the US-led West, more Chinese biotechs are actively seeking growth opportunities in the vast emerging markets, or the markets outside the USA and European Union, especially the geographically nascent ASEAN region and the wealthy Middle East region. But experts said companies must take risks into account before making decisions.

“Drug approval process, (policy) transparency and compliance with International Council for Harmonization (ICH) guidelines are the three major risks I suggest biotechs should pay attention to,” Zeng Yali, a Beijing-based consultant with Clarivate Analytics, said at an online meeting.